Moderna and Merck Report Positive Phase 3 Results: Personalized mRNA Vaccine Cuts Melanoma Recurrence

Moderna and Merck reported that a personalized mRNA vaccine, intismeran, given with Merck’s Keytruda significantly reduced melanoma recurrence and prevented spread to other organs in a large Phase 3 trial of 1,...



























